三水杨酸胆碱镁(Choline Magnesium Trisalicylate) - 在研适应症：骨关节炎，类风湿关节炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Tricosal

靶点-

作用方式-

作用机制-

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

骨关节炎类风湿关节炎

非在研适应症-

原研机构-

在研机构-

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C26H29MgNO10

InChIKeyFQCQGOZEWWPOKI-UHFFFAOYSA-K

CAS号64425-90-7

关联

3

项与三水杨酸胆碱镁相关的临床试验

NCT01009931

/ Terminated临床2期IIT

A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia

This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.

开始日期2011-03-01

申办/合作机构

Rutgers State University of New Jersey

[+3]

NCT02144675

/ Completed临床2期IIT

A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia

This randomized phase II trial studies how well choline magnesium trisalicylate with idarubicin and cytarabine works in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as choline magnesium trisalicylate, idarubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet know whether choline magnesium trisalicylate and combination chemotherapy is more effective than combination chemotherapy alone in treating patients with acute myeloid leukemia.

开始日期2009-01-01

申办/合作机构

Rutgers State University of New Jersey

[+2]

NCT00156299

/ Terminated临床1期IIT

A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML)

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in cancer cells. It may also help doctors understand how cancer cells respond to treatment with choline magnesium trisalicylate.
PURPOSE: This pilot clinical trial is studying gene expression in cancer cells during chemotherapy and the safety of choline magnesium trisalicylate in treating patients with newly diagnosed acute myeloid leukemia.

开始日期2003-03-01

申办/合作机构

Rutgers State University of New Jersey

[+1]

100 项与三水杨酸胆碱镁相关的临床结果

登录后查看更多信息

100 项与三水杨酸胆碱镁相关的转化医学

登录后查看更多信息

100 项与三水杨酸胆碱镁相关的专利（医药）

登录后查看更多信息

48

项与三水杨酸胆碱镁相关的文献（医药）

2019-07-10·Journal of Clinical Oncology1区 · 医学

Comparative Efficacy of Therapeutics for Chronic Cancer Pain: A Bayesian Network Meta-Analysis

1区 · 医学

Article

作者: Liu, Hongli ; Huang, Rongzhong ; Cao, Yu ; Ping, Minsheng ; Chen, Yuqing ; Jiang, Lihong ; Xu, Yu ; Ning, Jie ; Wang, Xiaojing ; Li, Wei

PURPOSE Opioids are the primary choice for managing chronic cancer pain. However, many nonopioid therapies are currently prescribed for chronic cancer pain with little published evidence comparing their efficacy. METHODS Electronic databases were searched for randomized controlled trials (RCTs) comparing any systemic pharmaceutical intervention and/or combination thereof in treating chronic cancer pain. The primary outcome was global efficacy reported as an odds ratio (OR). The secondary outcome was change in pain intensity reported as a standardized mean difference (SMD). RESULTS We included 81 RCTs consisting of 10,003 patients investigating 11 medication classes. Most RCTs (80%) displayed low risk of bias. The top-ranking classes for global efficacy were nonopioid analgesics (network OR, 0.30; 95% credibility interval [CrI], 0.13 to 0.67), nonsteroidal anti-inflammatory drugs (network OR, 0.44; 95% CrI, 0.22 to 0.90), and opioids (network OR, 0.49; 95% CrI, 0.27 to 0.86), whereas the top-ranked interventions were lidocaine (network OR, 0.04; 95% CrI, 0.01 to 0.18; surface under the cumulative ranking curve analysis [SUCRA] score, 98.1), codeine plus aspirin (network OR, 0.22; 95% CrI, 0.08 to 0.63; SUCRA score, 81.1), and pregabalin (network OR, 0.29; 95% CrI, 0.08 to 0.92; SUCRA score, 73.8). In terms of reducing pain intensity, we found that no class was superior to placebo, whereas the following top-ranked interventions were superior to placebo: ziconotide (network SMD, −24.98; 95% CrI, −32.62 to −17.35; SUCRA score, 99.8), dezocine (network SMD, −13.56; 95% CrI, −23.37 to −3.69; SUCRA score, 93.5), and diclofenac (network SMD, −11.22; 95% CrI, −15.91 to −5.80; SUCRA score, 92.9). CONCLUSION There are significant differences in efficacy among current regimens for chronic cancer pain. Our evidence suggests that certain nonopioid analgesics and nonsteroidal anti-inflammatory drugs can serve as effectively as opioids in managing chronic cancer pain.

2017-05-04·Leukemia & Lymphoma

Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy

Letter

作者: Walton, Kelly ; Patel, Vimal ; Medina, Daniel ; Gharibo, Mecide ; Aisner, Joseph ; David, Kevin ; Strair, Roger ; Lin, Yong ; Bannerji, Rajat ; Schaar, Dale ; Rabson, Arnold B.

Nuclear factor kappa B (NF-κB) is constitutively expressed in many primary acute myelogenous leukemia (AML) and leukemic stem cell (LSC) samples. Inhibition of nuclear NF-κB ex vivo results in cyto...

2017-04-17·Chemical Research in Toxicology3区 · 医学

Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes

3区 · 医学

Article

作者: Dang, Na Le ; Hughes, Tyler B. ; Miller, Grover P. ; Swamidass, S. Joshua

Structural alerts are commonly used in drug discovery to identify molecules likely to form reactive metabolites and thereby become toxic. Unfortunately, as useful as structural alerts are, they do not effectively model if, when, and why metabolism renders safe molecules toxic. Toxicity due to a specific structural alert is highly conditional, depending on the metabolism of the alert, the reactivity of its metabolites, dosage, and competing detoxification pathways. A systems approach, which explicitly models these pathways, could more effectively assess the toxicity risk of drug candidates. In this study, we demonstrated that mathematical models of P450 metabolism can predict the context-specific probability that a structural alert will be bioactivated in a given molecule. This study focuses on the furan, phenol, nitroaromatic, and thiophene alerts. Each of these structural alerts can produce reactive metabolites through certain metabolic pathways but not always. We tested whether our metabolism modeling approach, XenoSite, can predict when a given molecule's alerts will be bioactivated. Specifically, we used models of epoxidation, quinone formation, reduction, and sulfur-oxidation to predict the bioactivation of furan-, phenol-, nitroaromatic-, and thiophene-containing drugs. Our models separated bioactivated and not-bioactivated furan-, phenol-, nitroaromatic-, and thiophene-containing drugs with AUC performances of 100%, 73%, 93%, and 88%, respectively. Metabolism models accurately predict whether alerts are bioactivated and thus serve as a practical approach to improve the interpretability and usefulness of structural alerts. We expect that this same computational approach can be extended to most other structural alerts and later integrated into toxicity risk models. This advance is one necessary step toward our long-term goal of building comprehensive metabolic models of bioactivation and detoxification to guide assessment and design of new therapeutic molecules.

100 项与三水杨酸胆碱镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07694	-	-	DB01401

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	中国	-	-
类风湿关节炎	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02144675 (CTgov)	临床2期	伴del(5q)成人急性髓系白血病 \| 急性髓单核细胞白血病 \| 伴有 11q23 异常的急性髓系白血病 \| 成人急性单核细胞白血病 \| 急性红细胞白血病 \| 急性巨核细胞白血病	27	laboratory biomarker analysis+choline magnesium trisalicylate+Cytarabine+idarubicin (Arm I (Choline Magnesium Trisalicylate and Chemotherapy))	製獵願選鹹壓夢淵鬱夢(襯網積網構醖鹹顧夢鑰) = 簾窪艱膚鏇選遞淵廠鑰壓齋膚蓋廠襯襯衊網憲 (醖膚觸鏇選願糧獵願窪, 構糧網鏇膚顧獵積積醖 ~ 窪憲衊遞獵願醖襯齋糧) 更多	-	2018-07-24
NCT02144675 (CTgov)	临床2期		27	laboratory biomarker analysis+Cytarabine+idarubicin (Arm II (Chemotherapy))	製獵願選鹹壓夢淵鬱夢(襯網積網構醖鹹顧夢鑰) = 製憲簾顧繭醖獵蓋觸觸壓齋膚蓋廠襯襯衊網憲 (醖膚觸鏇選願糧獵願窪, 鹹夢範繭獵積淵願齋糧 ~ 網艱鏇衊鏇壓糧繭衊襯) 更多	-	2018-07-24
NCT01009931 (CTgov)	临床2期	急性髓性白血病 \| 复发性急性髓细胞白血病	1	Choline magnesium trisalicylate+12-O-tetradecanoylphorbol-13-acetate+Dexamethasone	鏇蓋淵選築願膚鏇製艱(齋淵廠襯醖遞鏇醖淵選) = 齋選齋餘選糧鏇衊窪築積鑰鑰鬱遞繭鑰廠積夢 (築觸壓製憲鑰襯築繭網, 蓋獵鏇製顧襯積壓壓範 ~ 齋憲夢襯鬱膚範衊壓鹽) 更多	-	2015-06-22